Tech Company Financing Transactions
Metavention Funding Round
On 1/9/2018, Metavention secured $65 million in Series C investment from New Enterprise Associates, Andreessen Horowitz and RK Mellon.
Transaction Overview
Company Name
Announced On
1/9/2018
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series C
Investors
New Enterprise Associates (Lead Investor) (Justin Klein)
Sanderling Ventures (Timothy Mills)
Proceeds Purpose
Metavention will use the funds to optimize its novel transcatheter based Metabolic Neuromodulation Therapy (MNT) for glucose control in patients with Type 2 diabetes (T2D) and commence preparations for a Phase 2 study in the United States.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
10900 73rd Ave. North 101
Maple Grove, MN 55369
USA
Maple Grove, MN 55369
USA
Phone
Website
Email Address
Overview
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Todd Berg
Chief Financial Officer
James Ness
Founder
Bobak Azamian
VP - Manufacturing
Kent Lind
VP - Marketing
Steve Bosrock
VP - R & D
Vineel Vallapureddy
VP - Regulatory Affairs
Megan Brandt
Browse more venture capital transactions:
Prev: 1/9/2018: Voatz venture capital transaction
Next: 1/9/2018: Leading Pharma venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs